Cs Chim

List of Publications by Citations

85 papers	2,253 citations	24 h-index	45 g-index
93 ext. papers	2,518 ext. citations	6 avg, IF	4.68 L-index

#	Paper	IF	Citations
85	Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. *Blood*, **2004**, 103, 216-21	2.2	306
84	SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. *Blood*, **2004**, 103, 4630-5	2.2	197
83	Epigenetic inactivation of the miR-34a in hematological malignancies. *Carcinogenesis*, **2010**, 31, 745-50	4.6	144
82	Epigenetic inactivation of the miR-124-1 in haematological malignancies. *PLoS ONE*, **2011**, 6, e19027	3.7	99
81	Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. *Journal of Clinical Oncology*, **2001**, 19, 2033-40	2.2	97
80	Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. *Archives of Internal Medicine*, **2005**, 165, 2651-8		81
79	Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 2760-7	5.6	79
78	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFB pathway. *Molecular Cancer*, **2013**, 12, 173	42.1	60
77	Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. *Bone Marrow Transplantation*, **1997**, 19, 91-3	4.4	60
76	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. *American Journal of Hematology*, **2016**, 91, 575-80	7.1	60
75	Epigenetic silencing of MIR203 in multiple myeloma. *British Journal of Haematology*, **2011**, 154, 569-78	4.5	59
74	Methylation of p15 and p16 genes in adult acute leukemia. *Cancer*, **2001**, 91, 2222-2229	6.4	58
73	Epigenetic inactivation of the MIR34B/C in multiple myeloma. *Blood*, **2011**, 118, 5901-4	2.2	57
72	Epigenetic inactivation of the MIR129-2 in hematological malignancies. *Journal of Hematology and Oncology*, **2013**, 6, 16	22.4	50
71	Primary CD56 positive lymphomas of the gastrointestinal tract. *Cancer*, **2001**, 91, 525-33	6.4	50
70	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. *Molecular Cancer*, **2015**, 14, 175	42.1	37
69	Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. *Journal of Translational Medicine*, **2011**, 9, 197	8.5	36

68	Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. *Journal of Hematology and Oncology*, **2015**, 8, 103	22.4	33
67	Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. *Journal of Clinical Pathology*, **2007**, 60, 104-6	3.9	32
66	Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. *Journal of Translational Medicine*, **2014**, 12, 52	8.5	31
65	Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. *Journal of Clinical Pathology*, **2007**, 60, 664-9	3.9	29
64	Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. *Clinical Lymphoma and Myeloma*, **2008**, 8, 331-9		27
63	Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma. *Human Pathology*, **2007**, 38, 1849-57	3.7	26
62	Molecular detection of minimal residual disease in multiple myeloma. *British Journal of Haematology*, **2018**, 181, 11-26	4.5	25
61	Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. *Annals of Hematology*, **2017**, 96, 871-872	3	24
60	Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. *Leukemia Research*, **2006**, 30, 1135-9	2.7	24
59	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. *Epigenomics*, **2015**, 7, 985-1001	4.4	23
58	Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. *Oncotarget*, **2014**, 5, 9770-82	3.3	23
57	Meningeal relapse in Hodgkin's disease. *Journal of Clinical Oncology*, **2000**, 18, 1153-5	2.2	19
56	Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. *Oncotarget*, **2016**, 7, 82400-82410	3.3	19
55	High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. *Journal of Hematology and Oncology*, **2016**, 9, 107	22.4	18
54	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. *Clinical Epigenetics*, **2019**, 11, 71	7.7	16
53	LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. *European Journal of Haematology*, **2015**, 94, 330-5	3.8	16
52	RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNF in the microenvironment. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2014**, 1843, 1834-8	4.9	16
51	Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. *Oncotarget*, **2015**, 6, 44422-36	3.3	16

50	Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma. *Journal of Clinical Oncology*, **2005**, 23, 2426-8	2.2	15
49	Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. *Expert Review of Molecular Diagnostics*, **2012**, 12, 755-65	3.8	14
48	Primary granulocytic sarcoma of the mediastinum. *Leukemia and Lymphoma*, **2004**, 45, 1931-3	1.9	13
47	Unusual abdominal tumors: case 3. Multiple lymphomatous polyposis in lymphoma of colon. *Journal of Clinical Oncology*, **2003**, 21, 953-5	2.2	13
46	Two unusual lymphomas. Case 2: pulmonary intravascular lymphomatosis. *Journal of Clinical Oncology*, **2000**, 18, 3733-5	2.2	13
45	Epigenetic silencing of EVL/miR-342 in multiple myeloma. *Translational Research*, **2018**, 192, 46-53	11	12
44	Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. *Frontiers in Oncology*, **2019**, 9, 449	5.3	11
43	Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. *Cancer Cell International*, **2013**, 13, 122	6.4	11
42	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. *Journal of Hematology and Oncology*, **2012**, 5, 28	22.4	11
41	DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin's Lymphomas. *Frontiers in Genetics* , **2012**, 3, 233	4.5	11
40	Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. *Leukemia and Lymphoma*, **2006**, 47, 815-25	1.9	11
39	Epigenetic silencing of LPP/miR-28 in multiple myeloma. *Journal of Clinical Pathology*, **2018**, 71, 253-258	3.9	11
38	Common malignancies with uncommon sites of presentation: case 2. Mantle-cell lymphoma of the prostate. *Journal of Clinical Oncology*, **2003**, 21, 4456-8	2.2	10
37	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. *Scientific Reports*, **2018**, 8, 13522	4.9	10
36	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. *Leukemia and Lymphoma*, **2018**, 59, 2305-2317	1.9	9
35	Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting. *Hematological Oncology*, **2020**, 38, 726-736	1.3	9
34	Restoration of chemosensitivity by bortezomib: implications for refractory myeloma. *Nature Reviews Clinical Oncology*, **2009**, 6, 237-40	19.4	8
33	Pulmonary interstitial amyloidosis complicating multiple myeloma. *Journal of Clinical Oncology*, **2008**, 26, 504-6	2.2	8

32	Primary follicular lymphoma of the small intestine. *Leukemia and Lymphoma*, **2004**, 45, 1463-6	1.9	8
31	Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. *Journal of Pharmacy and Pharmacology*, **2020**, 72, 728-737	4.8	7
30	Epigenetic silencing of long non-coding RNA in multiple myeloma: impact on prognosis and myeloma dissemination. *Cancer Cell International*, **2020**, 20, 403	6.4	7
29	Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. *Journal of Molecular Diagnostics*, **2020**, 22, 679-684	5.1	6
28	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. *American Journal of Hematology*, **2020**, 95, 503-509	7.1	6
27	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. *British Journal of Haematology*, **2020**, 190, 249-261	4.5	6
26	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. *Leukemia and Lymphoma*, **2019**, 60, 471-476	1.9	6
25	Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients. *Journal of Translational Medicine*, **2010**, 8, 124	8.5	6
24	Plasma cell problems: Case 2. Extramedullary cardiac plasmacytoma presenting with cardiac tamponade. *Journal of Clinical Oncology*, **2005**, 23, 3140-3	2.2	6
23	Bone marrow necrosis in bone marrow transplantation: the role of MR imaging. *Bone Marrow Transplantation*, **1998**, 22, 1125-8	4.4	5
22	Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature. *American Journal of Hematology*, **2005**, 79, 246-7	7.1	5
21	Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. *Annals of Hematology*, **2013**, 92, 855-7	3	4
20	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. *Clinical Epigenetics*, **2020**, 12, 150	7.7	4
19	Eosinophilic leukemic transformation in polycythemia rubra vera (PRV). *Leukemia and Lymphoma*, **2005**, 46, 447-50	1.9	3
18	Giant pronormoblasts in parvovirus-associated pure red cell aplasia. *American Journal of Hematology*, **2000**, 65, 289	7.1	3
17	Primary refractory multiple myeloma: a real-world experience with 85 cases. *Leukemia and Lymphoma*, **2020**, 61, 2868-2875	1.9	3
16	Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival. *Hematological Oncology*, **2014**, 32, 205-11	1.3	2
15	Mucosa-associated lymphoid tissue (MALT) lymphoma of the jejunum: an elusive cause of recurrent upper gastrointestinal bleeding. *Leukemia and Lymphoma*, **2004**, 45, 405-7	1.9	2

14	miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration. *Cell Communication and Signaling*, **2021**, 19, 62	7.5	2
13	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. *Leukemia and Lymphoma*, **2020**, 61, 1885-1893	1.9	2
12	Pathological bone fracture in non-Hodgkin's lymphoma. *Journal of Clinical Oncology*, **2007**, 25, 3175-6	2.2	1
11	Splenic rupture as the presenting symptom of blastic crisis in a patient with Philadelphia-negative, bcr-abl-positive ET. *American Journal of Hematology*, **2001**, 66, 70-1	7.1	1
10	Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience. *American Journal of Hematology*, **1999**, 61, 159-63	7.1	1
9	A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. *Scientific Reports*, **2021**, 11, 7009	4.9	1
8	Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses. *Clinical Epigenetics*, **2018**, 10, 158	7.7	1
7	Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone. *Blood*, **2021**, 138, 1648-1648	2.2	0
6	Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone. *Blood*, **2021**, 138, 1661-1661	2.2	0
5	3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. *Hematology*, **2021**, 26, 652-655	2.2	0
4	Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. *Frontiers in Oncology*, **2020**, 10, 611021	5.3	0
3	Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma. *Therapeutic Advances in Hematology*, **2021**, 12, 20406207211030369	5.7	0
2	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.. *Therapeutic Advances in Hematology*, **2022**, 13, 20406207221082043	5.7	0
1	Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma. *Hematology*, **2019**, 24, 533-537	2.2	